Lebrest 2.5mg tablets
Ferron Par Pharmaceuticals
Ingredients in every tablet
Each package contains
|ATC Level 1||L - Antineoplastic and immunomodulating agents|
|ATC Level 2||L02 - Endocrine Therapy Antineoplastic and Immunomodulating Agents|
|ATC Level 3||L02B - Hormone Antagonists and Related Agents|
18 YEARS OLD AND ABOVE
Adults and elderly patients. The recommended dose of letrozole is 2.5 mg once daily. In the adjuvant and extended adjuvant setting, treatment with letrozole should continue for 3 years or until tumor relapse occurs, whichever comes first. In patients with metastatic disease, treatment with letrozole should continue until tumor progression is evident. No dose adjustment is required for elderly patients. Patients with hepatic and/or renal impairment. No dosage adjustment is required for patients with mild to moderate hepatic impairment or renal impairment (creatinine clearance ≥10 ml/min).
Food does not affect the absorption of letrozole and the drug may be
administered without regard to meals.
HEPATIC AND/OR RENAL IMPAIRMENT
No dosage adjustment is required for patients with mild to moderate hepatic
impairment or renal impairment (creatinine clearance 10 ml/min).
– Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer Extended adjuvant treatment of early breast cancer in postmenopausal women, who have received 5 years of adjuvant tamoxifen therapy. Treatment in postmenopausal women with hormone-dependent advanced breast cancer. Treatment of advanced breast cancer in women with natural or artificially induced postmenopausal status, who have previously been treated with antiestrogens. Preoperative therapy in postmenopausal women with localized hormone receptor positive breast cancer, to allow subsequent breast-conserving surgery in women not originally considered candidates for this type of surgery. Subsequent treatment after surgery should be in accordance with standard of care.